Showing 2331-2340 of 3039 results for "".
- Inflammasome Therapeutics Announces First Patient Dosed in Phase 1 DME Study of the Dual Inflammasome Inhibitor K8https://modernod.com/news/inflammasome-therapeutics-announces-first-patient-dosed-in-phase-1-dme-study-of-the-dual-inflammasome-inhibitor-k8/2482069/Inflammasome Therapeutics announced the first patient has been dosed in a phase 1 study of a novel compound in the treatment of diabetic macular edema (DME). The 24-week study (ClinicalTrials.gov ID NCT05699759) is designed to assess safety and initial evidence of efficacy. Th
- Decision on the Adoption of a Sale Plan for Pixium Vision Postponedhttps://modernod.com/news/decision-on-the-adoption-of-a-sale-plan-for-pixium-vision-postponed/2482065/Pixium Vision announced that the decision of the Paris Commercial Court on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings has been postponed to a later date, which will be communicated by the company as soon as it becomes aware of it.</
- Zenni Optical Announces 2023 Eye Care Access Scholarship Winnershttps://modernod.com/news/zenni-optical-announces-2023-eye-care-access-scholarship-winners/2482062/Zenni Optical has awarded five optometry students with its 2023 Eye Care Access Scholarship. Now in its second year, the Zenni Eye Care Access Scholarship recognizes incoming students who want to provide eye care to communities in need everywhere.
- Amring Pharmaceuticals Names Jai G. Parekh, MD, Chief Commercial Officer, Eye Care, UShttps://modernod.com/news/amring-pharmaceuticals-names-jai-g-parekh-md-chief-commercial-officer-eye-care-us/2482059/Amring Pharmaceuticals, a subsidiary of Nordic Group BV, has named Jai G. Parekh, MD, MBA, as Chief Commercial Officer, Eye Care, US. Nordic Pharma recently expanded its pharmaceutical presence in the US by acquiring Visant Medical, maker of the FDA-c
- Harrow Launches Dry Eye Drug Vevye in the United Stateshttps://modernod.com/news/harrow-introduces-vevye-in-united-states-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2482053/Harrow announced that Vevye (cyclosporine ophthalmic solution) 0.1% is now available in the United States. It is indicated for treating the signs and symptoms of dry eye disease (DED). Vevye is the company’s nonpreserved, twice-daily dosed prescription drug based on a water free s
- Alimera Completes Recruitment for the Synchronicity Study Evaluating Yutiqhttps://modernod.com/news/alimera-completes-recruitment-for-the-synchronicity-study-evaluating-yutiq/2482044/Alimera Sciences announced that it has completed enrollment for the company’s Synchronicity study, a prospective, open-label clinical study evaluating the safety and efficacy of Yutiq (fluocinolone acetonide intravitreal implant 0.18mg) in the treatment of chronic noninfectious uveitis
- LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patientshttps://modernod.com/news/lumithera-provides-update-on-fda-review-of-valeda-treatment-for-dry-amd-patients/2482040/LumiThera announced an update on the regulatory status of the Valeda Light Delivery System. Following feedback from the FDA, a De Novo request to reclassify the Valeda Light Delivery System as a Class II device has been submitted for review. Under the De Novo request process, the V
- Harrow Partners with Healthcare Market Access Technology Platforms to Support Launch of Vevyehttps://modernod.com/news/harrow-partners-with-healthcare-market-access-technology-platforms-to-support-launch-of-vevye/2482037/Harrow announced that it has partnered with three healthcare technology platforms to expand US availability of dry eye drug Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) ophthalmic solution based on a water-free semifluorinated alkane (
- Pixium Vision: Date Scheduled for Decision on Adoption of a Sale Planhttps://modernod.com/news/pixium-vison-date-scheduled-for-decision-on-adoption-of-a-sale-plan/2482020/Pixium Vision SA announced that following a hearing on Monday, the Paris Commercial Court will issue its decision on January 16, 2024 on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings. In the event of the opening of judicial l
- Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-screened-in-the-whistler-phase-3b-trial-of-ncx-470-in-glaucoma/2482018/Nicox announced that the first patient has been screened in the Whistler phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in IOP lowering. NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, is the company's le